Replies to post #61 on Immatics NV (IMTX)

[FACT-MASTER]

Interesting development here with GSK

https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/

Excerpt from article:

"GSK did not respond to BioPharma Dive’s request for comment. The company has another cell therapy deal with German biotech Immatics Biotechnologies that’s focused on solid tumors."

The previous presentation coupled with, the recent capital raise, and now this info are all positive indicators for IMTX, imo.